INTRODUCTION
Clostridium difficile infection (CDI) has been increasingly recognized in recent years as an entity of primary importance that requires prompt diagnosis and efficient treatment to prevent a severe and complicated disease C. difficile, the impaired host intestinal microbiota and the altered immunity of CDI patients, current treatment strategies often have suboptimal results with regard to clinical cure and relapse prevention alike. In fact, present therapeutic options leave ample room for improvement in terms of clinical outcome, as the average cure rates achieved by the three main antibiotics currently recommended for CDI treatment (metronidazole, vancomycin and fidaxomicin [1, 2] ) do not exceed 80-90%
[3]. Although fidaxomicin boasts significantly lower relapse rates than the other two alternatives, sustained cure (that is cure without recurrence) may be as low as 75% among patients treated with this best available option [4, 5] .
The urgent need for more efficient tools to fight CDI makes it unsurprising that today there are an impressive number of novel antibiotics and other therapies at different stages of development, some of them already being tested in phase III randomized controlled trials (RCTs). At the same time, some long-known drugs that are currently not recommended for CDI have been revisited lately to check whether there is potential room for them in the arsenal of anti-CDI therapeutics. The aim of this review is to summarize novel, neglected and controversial CDI treatment options, some of which may become part of everyday practice in the near future.
There are various criteria according to which one may classify these therapies (mode of administration, predominantly prophylactic vs. therapeutic agents, natural vs. synthetic products, etc.). In this article we resume them according to the major therapeutic effect that is sought by their application (Fig. 1) .
Accordingly, the majority of these products can fit in one of the following categories: (1) antibiotics and non-antibiotic agents with bacteriostatic/bactericidal effect against C.
difficile; (2) toxin-neutralizing agents; (3) therapies that boost host immune defense against CDI; (4) treatments that modulate the intestinal environment to make it less favorable for C. difficile colonization;
anti-inflammatory substances that prevent or reduce enterocyte damage caused by C. difficile toxins. Table 1 summarizes all therapies discussed in the following, along with their current phase of development.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
ANTIBIOTICS AND NON-ANTIBIOTIC ANTICLOSTRIDIAL AGENTS
Similarly to the three main currently recommended anti-clostridial drugs, the majority of off-label and experimental therapeutic options seek to have a direct effect on the causative microorganism. These antibiotics and non-antibiotic agents target certain molecular components of C. difficile with the aim of eliminating the bacteria in an already established infection. They are presented in the following, grouped according to their main mechanism of action.
Inhibitors of Transcription and DNA

Synthesis
Rifamycins
Rifaximin is a semisynthetic, nonabsorbable derivative of rifamycin that inhibits bacterial RNA synthesis, primarily used in the treatment of traveler's diarrhea and hepatic encephalopathy. It is considered to have very little and rather beneficial effect on the normal intestinal microbiota [6, 7] , though its complete innocuousness in patients receiving long-term rifaximin treatment is questionable [8] . It was equally efficient as vancomycin in a hamster model of CDI, and-depending on the C. difficile strain used-similar or lower recurrence rates were observed after rifaximin withdrawal as compared to the vancomycin group [9] .
There have been various retrospective and prospective clinical case series demonstrating its efficacy in first CDI episodes, as well as in recurrent and refractory CDI [10] [11] [12] [13] , but rifaximin failed to unmistakably demonstrate non-inferiority to vancomycin in a RCT [14] . Its somewhat higher resistance rates as compared to vancomycin and metronidazole-especially A Disruption of healthy gut microbiota and C. difficile colonization-therapy aiming to protect or to restore the intestinal microbiota; B C. difficile germination and outgrowth-antibiotics and non-antibiotic agents targeting C. difficile; C toxin secretion-toxin-neutralizing agents; D toxin-mediated enterocyte damage and activation of the innate immune system-therapy aiming to alleviate intestinal mucosa inflammation; E adaptive immune system activation-active immunotherapy. The figure does not pretend to depict the entire process in its completeness but rather focuses on the main steps that are interfered with by the different treatment modalities detailed in the article. Important components of C. difficile pathogenesis and host defense (endosomes, cytoskeleton, dendritic cells, mucus layer, bile acids, etc.) are deliberately missing from the image 
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Hybrid Antibiotics and Other Agents with Multiple Mechanisms of Action
Cadazolid is a new fluoroquinoloneoxazolidinone antibiotic by Actelion, which exerts its antibacterial effect principally by the inhibition of protein synthesis and to a lesser degree also interferes with bacterial DNA synthesis [111] . Cadazolid not only has lower MICs against C. difficile than vancomycin and even fidaxomicin [112, 113] , but it is also highly active against vancomycin resistant Enterococci, a major threat in vancomycin-treated patients, minimizing the risk of patient colonization by this much-dreaded bacteria [114] . This, combined with its potent activity against toxin formation and sporulation, makes it a promising new recruit among anticlostridial drugs. It performed well in a phase II trial as compared to vancomycin in first episodes or first recurrences of CDI [115] , and it is currently being tested in two phase III clinical trials [116] .
MCB3681, a novel fluoroquinolone-oxazolidinone antibiotic by Morphochem, also proved to possess excellent in vitro efficacy against C. difficile [117] . In a phase I study its water-soluble prodrug, and piglets [122] ), but human studies have not yet been announced by its developer, Microbiotix.
Ramizol is the first member of a new antibiotic family that selectively targets the mechanosensitive ion channel of large conductance (MscL) in bacteria [123] and possesses potent antioxidant properties as well [124] . In a hamster model of CDI orally administered Ramizol conferred lower 28-day survival than vancomycin (57% vs. 86%), and its spore-clearing capacity was also inferior to that of vancomycin (29-57% vs. 100%) [125] . . Its role in C. difficile toxin-neutralization was suggested by one study [128] , and direct C. difficile cell killing was observed in another one with physiological concentrations of HD5 [129] . Whether these characteristics of HD5 may be exploited in the fight against C. difficile is unclear.
Certain medium-chain fatty acids, such as lauric acid derived from virgin coconut oil, caused a significant inhibition of C. difficile growth in an in vitro study [130] . It is postulated that bacterial cell death is caused by the incorporation of these fatty acids in the bacterial cell membrane that brings forth a substantial change in its permeability as well as by a probable interference with cellular metabolism [131] . In vivo studies on the efficacy of virgin coconut oil or its derivatives in the prevention or treatment of CDI have not yet been undertaken.
Agents of Unknown/Unclear Mechanism of Action
Ridinilazole (previously SMT19969) is a narrow-spectrum antibiotic with poor oral bioavailability that exhibits 2-17 times lower MIC values against C. difficile than vancomycin [132] [133] [134] . Its precise mechanism of action is not yet fully known, but it had a potent bactericidal effect on C. difficile, caused significant reduction of toxin levels and also demonstrated anti-inflammatory activity in vitro on human intestinal cells [135] . In a hamster model, better 28-day survival rates were observed in animals treated with ridinilazole than in the ones given vancomycin or fidaxomicin [136] . A phase II RCT was completed recently, where ridinilazole achieved the non-inferiority goal set in terms of clinical cure and was superior to vancomycin in terms of sustained clinical response after 30 days of follow-up [137] . Summit
Therapeutics is currently preparing phase III RCTs with this compound [138] . Berberine is a natural substance already utilized in ancient Chinese folk medicine. The addition of berberine to vancomycin significantly improved mortality, prevented weight loss and decreased recurrence rates in a mouse model of CDI [139] . The authors speculated that berberine may counteract the deleterious effect of vancomycin on intestinal microbiota by inhibiting the expansion of Enterobacteriaceae. A recent in vitro study, however, showed a high berberine uptake of germinating C. difficile spores where it may reach elevated concentrations, inhibiting spore outgrowth on its own [140] .
The bacteriostatic effect of bovine lactoferrin on Clostridium species has been known for more than 20 years [141] 
Passive Immunization
The potential of colostrum of pregnant cows immunized with C. difficile toxoids (hyperimmune bovine colostrum, HBC) to inhibit the cytotoxic and enterotoxic effect of C. difficile toxins has been known for more than 2 decades [161, 162] . Recently, it was proved to alleviate symptoms of CDI in gnotobiotic piglets without detectably affecting normal intestinal microbiota [163] . Whey protein concentrate derived from immunized cow milk was proved to be safe and well tolerated in human subjects with CDI as well [164] . A randomized phase II study comparing the efficacy of immune whey with metronidazole in the treatment of recurrent CDI showed similar clinical results to the two treatment modalities, but was terminated prematurely because of the bankruptcy of the sponsor (Novatreat Ltd.) [165] .
The use of intravenous immunoglobuline (IVIG) in CDI has been subject to discussion for decades, but in the absence of evidence from RCTs its potential benefits remain controversial [166, 167] . There are only two relatively small retrospective matched cohort studies published that compare the clinical efficacy of the addition of IVIG to conventional anti-clostridial treatment [168, 169] . Neither of them found significant differences between the compared cohorts in the main clinical outcomes, though the authors of one of these studies point out that in their IVIG cohort there were significantly older patients with more severe CDI than in the control group [169] .
The results of the first study on the efficacy of monoclonal antibodies against C. difficile toxin A (actoxumab, previously MK3415) and toxin B (bezlotoxumab, previously MK6072 and MDX1388) in a hamster model of CDI were published exactly 10 years ago [170] . In that study enhanced efficacy was observed with the combination of the two antibodies in terms of both recurrences and mortality. In a phase II trial with this combination (a.k.a. MK-3415A), the addition of the neutralizing antibodies to standard CDI treatment also significantly lowered recurrence rates [171] . However, although the efficacy of bezlotoxumab in preventing CDI recurrence was confirmed in two recently conducted phase III trials, its combination with actozumab, surprisingly, did not show any additional benefit in these studies [172] . Based on these results the US Food and Drug Administration (FDA) has very recently approved bezlotoxumab, and it will be available in the first quarter of 2017 [173] .
There are several other companies and research entities as well focusing on monoclonal antibodies against C. difficile toxins. A mixture of anti-A and anti-B neutralizing antibodies of ovine origin (PolyCAB) is under research by MicroPharm, which showed a significant reduction of CDI recurrence in a hamster model [174] . Phase I trials with this product are currently ongoing [182] and in two phase I studies [183] , ACAM-CDIFF recently passed a phase II trial without any safety issues [184] . A phase III RCT with this vaccine is currently ongoing [185] .
Pfizer is developing another toxoid vaccine (PF-06425090) with good results obtained in a phase I clinical trial [186] , and two phase II trials with this product are currently under way in healthy adults [187] .
VLA84 (a.k.a. IC84), a recombinant protein vaccine containing epitopes of toxin A and toxin B developed by Valneva, showed positive results in a recent phase II trial in terms of safety, tolerability and immunogenicity in both younger adults and elderly volunteers [188] . The vaccine is soon to be tested in a phase III RCT, according to the company [189] .
DNA Vaccines
DNA vaccines have the theoretical advantage over conventional vaccination of inducing not only humoral but also cellular immune response. The first DNA vaccine candidate for C. difficile encoded the receptor-binding site (RBD) of C. difficile toxin A [190] . Inoculated mice produced a potent antibody response to toxin A, and up to 100% survival was observed (depending on vaccine formulation and mouse strain) after challenge with a lethal dose of toxin A [190] .
In another mouse model, apart from the RBD of toxin A, the N-terminal enzymatic domain of toxin B also showed a positive antibody response [191] . The combination of the antibodies elicited by these two DNA vaccines conferred 100% protection against C. difficile in the experimental animals [191] .
More recently, promising results were published with a novel DNA vaccine that contains plasmids encoding optimized RBDs of both toxin A and B of C. difficile [192] . The sera of immunized animals (mice and primates) showed potent toxin neutralization ability in vitro, and the combined vaccine provided a 50-90% protection against a lethal dose of C.
difficile spores in mice [192] . conferred only moderate protection against a lethal C. difficile challenge in hamsters and mice [193] . Intra-rectal vaccination with the precursor protein SlpA in another animal study resulted in slightly more favorable results, as it significantly decreased the colonization level in the vaccinated mouse group, though it also failed to provide significant benefit in terms of survival [194] . The immunogenicity and protective ability of the protease Cwp84 have also been investigated in hamsters: rectally administered Cwp84 partially inhibited intestinal colonization and significantly increased the survival of hamsters challenged with C. difficile in one study [195] , and similar survival rates (40%) were observed in another one with the intragastric administration of the same vaccine encapsulated in pectin beads [196] . in a recent study, while leaving the rest of the intestinal microbiota apparently intact [198] .
All three known surface polysaccharides of C. difficile have been proved to be capable of eliciting a certain level of immune response.
PS-I was first detected on the hypervirulent C. difficile strain 027 but it is not specific to this ribotype [199] . Conjugates of either synthetic PS-I or its disaccharide minimal immunogenic epitope with the diphtheria toxin variant CRM 197 proved immunogenic in mice [200] .
Another murine model demonstrated the immunogenicity of a conjugate vaccine of a synthetic hexasaccharide epitope of PS-II with CRM 197 [201] , and PS-II-specific immune response was observed in swine as well after being vaccinated with a non-adjuvanted PSI/ PSII preparation [199] . In a recent study a conjugate vaccine of lipoteichoic acid (LTA, a.k.a. PS-III) and CRM 197 not only evoked antigen-specific immune response in a mouse model, but also significantly inhibited intestinal C. difficile colonization [202] .
There are a number of other potential C.
difficile vaccine candidates in the preclinical phase of investigation that may be tested in the clinical setting as well in the forthcoming years [203, 204] .
RESTORATION AND MODULATION OF THE INTESTINAL MICROBIOTA
Preservation and/or restoration of colonization resistance of the intestinal microbiota is the primary objective of the following therapies with subsequent protection against toxigenic C. difficile colonization or its elimination from the colon. Among these methods there are some that endeavor to offer the most complete solution for the problem of CDI, aiming to achieve clinical cure and the prevention of carriage, transmission and recurrences all at once.
Microbiota Restoration
The microbiota-restoring therapy par excellence is intestinal microbiota transplantation, which has been living a true renaissance in the last years. Its excellent clinical efficacy is further upheld by the observation that host intestinal microbiota composition and diversity are intimately linked to CDI severity and recurrence risk [205] .
That the restoration of an impaired intestinal microbiota by transplanting feces of a healthy individual may effectively cure CDI and prevent recurrences is not questioned any more [1, 20] . Its efficacy was proven in two already published phase II RCTs [206, 207] , and another phase II RCT performed on pediatric patients has also recently been completed [208] , whose results
are not yet available. Beside these completed studies there are various ongoing phase II and III RCTs with this treatment method [209] .
With the demonstration that the efficacy of previously recollected frozen and freshly harvested microbiota have the same efficacy, intestinal microbiota transplantation has become a lot less cumbersome than before [210, 211] . However, the manipulation of feces and classical enteral administration methods (i.e., by nasogastric tube, rectal enemas or via colonoscopy) are not only laborious, but make this procedure rather unattractive for physicians and patients alike [212] [213] [214] Seres Therapeutics has recently developed SER-109, which contains around 50 species of feces-derived Firmicutes spores after the elimination of the rest of the microbiota with ethanol. In an uncontrolled study, it was administered orally in an encapsulated form to 30 patients with multiple CDI recurrences after an appropriate response of standard of care antibiotic treatment, and no further recurrences were observed during the 8-week-long follow-up in 96.7% of the subjects [220] . A phase II trial to compare its efficacy with placebo is currently recruiting participants [221] . The same laboratory is investigating another microbial preparation comprised of spores of 12 different bacterial species (SER-262) meant to prevent recurrence after first CDI episodes [222] . An ongoing phase Ib RCT is currently evaluating the efficacy of this product as compared to placebo [223] .
MET-1 (Microbial Ecosystem Therapeutic-1) is a defined intestinal bacterial culture originating from a single donor. Two patients with recurrent CDI who were treated with this product experienced clinical cure in 2-3 days and remained recurrence free for the 6 following months [224] . An open-label pilot study is about to be initiated to demonstrate its efficacy in recurrent CDI in comparison with vancomycin [225] .
The administration of nontoxigenic C. difficile strains is another original approach to prevent colonization by toxigenic C. difficile. The most advanced research is being done with the nontoxigenic C. difficile strain M3
(NTCD-M3, a.k.a. VP20621), with encouraging results in animals [226] and in a recent phase II placebo-controlled human trial as well [227] . Another nontoxigenic strain, CD37, also provided significant protection against CDI in a mouse model as observed by less weight loss and less mortality in mice treated as compared to untreated animals [228] .
Bile Acid Therapy
The bile acid composition of the gut has an important role in the upholding of colonization resistance, as certain secondary bile acids formed by members of a healthy microbiota have an important role in the inhibition of C. Alanyl-glutamine is a bipeptide derived from glutamine with enhanced stability and water solubility. Its capacity both in vitro and in vivo to counteract cytotoxic activity of C. difficile toxins A and B was demonstrated in different studies [243, 244] . In a mouse CDI model the addition of alanyl-glutamine to vancomycin treatment resulted in improved survival as compared to vancomycin treatment alone efficiently reversed histopathologic damage caused by toxin A in another animal study [248] . No human studies have been conducted with these products for the time being.
CONCLUDING REMARKS
The number of potential therapies for CDI has been growing steadily recently, and this trend may continue for some years, as both the incidence and severity of C. difficile keep increasing, and current therapeutics cannot offer a definite solution for this situation. 
